Congress Urged To Address Expanded OMB Role In Regulations, Guidances
This article was originally published in The Gray Sheet
Executive Summary
The nonpartisan government watchdog group OMB Watch is urging Congress to take action against an executive order that increases the administration's influence over regulations and guidance documents issued by FDA and other agencies
You may also be interested in...
House To Probe Presidential Oversight Of Agency Guidances, Regs
Two House subcommittees are planning a joint hearing on amended 1Executive Order 12866, which institutionalizes the review of federal agency regulations and guidance documents by presidential appointees
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.